%PDF-1.4 % 41 0 obj <> endobj 38 0 obj <> endobj 123 0 obj <>stream Acrobat Distiller 4.05 for Macintosh 2004-10-07T18:31:03Z 2024-03-28T22:48:19-07:00 QuarkXPressª 4.11: AdobePS 8.8.0 (301) 2024-03-28T22:48:19-07:00 application/pdf Heather 2003-691.nov uuid:7eb1aeba-1dd2-11b2-0a00-7e09271d5700 uuid:7eb1aebe-1dd2-11b2-0a00-bf0000000000 endstream endobj 27 0 obj <> endobj 28 0 obj <> endobj 42 0 obj <>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 13 0 R/Type/Page>> endobj 1 0 obj <>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 15 0 R/Type/Page>> endobj 4 0 obj <>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>> endobj 7 0 obj <>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>> endobj 10 0 obj <>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>> endobj 142 0 obj [146 0 R] endobj 143 0 obj <>stream q 0 0 612 792 re W n BT 0.85091 0.85091 0.85091 rg /T1_0 19 Tf 0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm (Personal non-commercial use only. The Journal of Rheumatology. Copyright\ \251 2004. All rights reserved)Tj ET Q 1 g /GS0 gs 0 792 m 0 792 l f q 12 789 587 -785 re W n q 0 792.03 612 -792 re W n BT 0 0 0 1 k /GS1 gs /T1_1 1 Tf -0.00011 Tc 10 0 0 10 53.968 735.1616 Tm (ACKNOWLEDGMENT)Tj /T1_2 1 Tf 0.0551 Tw 8 0 0 8 53.968 725.1616 Tm [(W)79.9 (e thank all the pediatricians who participated in the survey and enabled\ )]TJ 0.3163 Tw 0 -1.25 TD [(its realization. )17.7 (W)79.9 (e also thank Dr)54.8 (. Janet Gardner)19.7 (-Medwin, Consultant)]TJ 0.1671 Tw T* [(Pediatric Rheumatologist, Glasgow)64.9 (, UK, for helpful comments; Dr)54.8 (. Ing)]TJ 0.2325 Tw T* (Jaroslav Chl\207dek, Faculty of Medicine, Hradec Kr\207lov\216, for stat\ istical)Tj 0.02499 Tw T* [(advice; and Blanka )54.8 (Aubrechtov\207 for secretarial assistance.)]TJ /T1_1 1 Tf 0 Tw 10 0 0 10 53.968 661.1616 Tm (REFERENCES)Tj /T1_2 1 Tf 0.02499 Tw 8 0 0 8 60.968 651.1616 Tm [(1.)-875.1 (Demography)64.8 (. In: Czech Health Statistics 1997. Prague: 1998.)]TJ T* [(2.)-875.1 (Czech Statistical Of)17.7 (fice Report; 1992.)]TJ T* [(3.)-875.1 (Gardner)19.7 (-Medwin JMM, Dolezalova P)110.7 (,)-0.1 ( Cummins C, Southwood)]TJ 1.675 -1.25 Td [(TR. Ethnic dif)17.7 (ferences in the incidence of Henoch-Sch\232nlein )]TJ T* (purpura, Kawasaki disease and rare vasculitides in children. Lancet)Tj 0 Tc 0 Tw T* [(2002;360:1)36.9 (197-202.)]TJ -0.00011 Tc 0.02499 Tw -1.675 -1.25 Td [(4.)-875.1 (Mills JA, Michel BA, Bloch DA, et al. )17.7 (The )54.8 (American College of)]TJ 1.675 -1.25 Td (Rheumatology 1990 criteria for the classification of )Tj T* [(Henoch-Sch\232nlein purpura. )54.8 (Arthritis Rheum 1990;33:1)36.8 (1)36.8 (14-21.)]TJ -1.675 -1.25 Td [(5.)-875.1 (American Heart )54.8 (Association Committee on rheumatic fever)39.7 (, )]TJ 1.675 -1.25 Td (endocarditis and Kawasaki disease. Diagnostic guidelines for)Tj T* [(Kawasaki disease. )54.8 (Am J Dis Child 1990;144:1218-9. )]TJ -1.675 -1.25 Td [(6.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ 1.675 -1.25 Td [(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ 0 Tc 0 Tw T* (1982;25:1271-7.)Tj -0.00011 Tc 0.02499 Tw -1.675 -1.25 Td [(7.)-875.1 (Bohan )54.8 (A, Peter JB. Polymyositis and dermatomyositis. N Engl )]TJ 0 Tc 1.675 -1.25 Td (J Med 1975;292:344-7, 403-7.)Tj -0.00011 Tc -1.675 -1.25 Td [(8.)-875.1 (Leavitt R)54.8 (Y)128.9 (, Fauci )54.8 (AS, Bloch DA, et al. )17.7 (The )54.8 (American College of)]TJ 1.675 -1.25 Td [(Rheumatology 1990 criteria for the classification of )17.7 (W)79.9 (egener)-37 (\325)55.1 (s)]TJ T* [(granulomatosis. )54.8 (Arthritis Rheum 1990;33:1)36.8 (101-7.)]TJ -1.675 -1.25 Td [(9.)-875.1 (Jennette JC, Falk RJ, )54.8 (Andrassy K, et al. Nomenclature of systemic)]TJ 1.675 -1.25 Td [(vasculitides. )54.8 (Arthritis Rheum 1994;37:187-92.)]TJ -2.175 -1.25 Td [(10.)-875.1 (Arend )17.7 (WP)110.7 (, Michel BA, Bloch DA, et al. )17.7 (The )54.8 (American College of)]TJ 2.175 -1.25 Td [(Rheumatology 1990 criteria for the classification of )17.7 (T)69.9 (akayasu)]TJ T* [(arteritis. )54.8 (Arthritis Rheum 1990;33:1)36.8 (129-34.)]TJ -2.1381 -1.25 Td [(1)36.8 (1)-0.1 (.)-875.1 (Stewart M, Savage JM, Bell B, McCord B. Long term renal )]TJ 2.1381 -1.25 Td (prognosis of Henoch-Sch\232nlein purpura in an unselected childhood)Tj T* [(population. Eur J Pediatr 1988;147:1)36.8 (13-5.)]TJ -2.175 -1.25 Td [(12.)-875.1 (Nielsen HE. Epidemiology of Sch\232nlein-Henoch purpura. )54.8 (Acta)]TJ 2.175 -1.25 Td (Paediatr Scand 1988;77:125-31.)Tj -2.175 -1.25 Td [(13.)-875.1 (Kaku )36.8 (Y)128.9 (, Nohara K, Honda S. Renal involvement in )]TJ 2.175 -1.25 Td [(Henoch-Sch\232nlein purpura: )54.8 (A)-220.1 (multivariate analysis of prognostic)]TJ T* (factors. Kidney Int 1998;53:1755-9.)Tj -2.175 -1.25 Td [(14.)-875.1 (Balmelli C, Laux-End R, Di Rocco D, Carvajal-Busslinger MI,)]TJ 2.175 -1.25 Td (Bianchetti MG. Schoenlein-Henoch purpura: course in 139 )Tj T* [(children. Schweiz Med )17.7 (W)79.9 (ochenschr 1996;24:293-8.)]TJ -2.175 -1.25 Td [(15.)-875.1 (Reinehr )17.7 (T)74 (, B\237rk G, Ber)17.7 (ger )17.7 (T)74 (, Doeker B, )54.8 (Andler )17.7 (W)91.8 (. Steroids for)]TJ 2.175 -1.25 Td (prophylaxis of Henoch-Sch\232nlein purpura nephropathy? Follow up)Tj T* (of 171 patients. Klin P\212diatr 2000;212:99-102.)Tj -2.175 -1.25 Td [(16.)-875.1 (Mollica F)79.7 (, Li )17.7 (V)128.9 (olti S, Garozzo R, Russo G. Ef)17.7 (fectiveness of early)]TJ 2.175 -1.25 Td (prednisone treatment in preventing the development of )Tj T* (nephropathy in anaphylactoid purpura. Eur J Pediatr )Tj 0 Tc 0 Tw T* (1992;151:140-4.)Tj -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(17.)-875.1 (Buchanec J, Balanda )17.7 (V)128.9 (, Belakova S, Minarik M, Zibolen M.)]TJ 2.175 -1.25 Td (Incidence of renal complications in Sch\232nlein-Henoch purpura )Tj T* (syndrome in dependence of early administration of steroids. Int )Tj T* (J Nephrol 1988;20:409-12.)Tj 30.7 68.171 Td [(18.)-875.1 (Saulsbury FT)73.9 (. Corticosteroid therapy does not prevent nephritis in)]TJ 2.175 -1.25 Td (Henoch-Sch\232nlein purpura. Pediatr Nephrol 1993;7:69-71.)Tj -2.175 -1.25 Td [(19.)-875.1 (Chang RK. Hospitalisations for Kawasaki disease among children)]TJ 2.175 -1.25 Td [(in the United States, 1988-1997. Pediatrics 2002;109:1)36.8 (162.)]TJ -2.175 -1.25 Td [(20.)-875.1 (Malleson PN, Fung MY)128.8 (, Rosenber)17.7 (g )54.8 (AM. )17.7 (The incidence of pediatric)]TJ 2.175 -1.25 Td (rheumatic diseases: Results from the Canadian Pediatric)Tj T* [(Rheumatology )54.8 (Association Disease Registry)64.8 (. J Rheumatol)]TJ 0 Tc 0 Tw T* (1996;23:1981-7.)Tj -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(21.)-875.1 (Y)99.8 (anagawa H, Nakamura )36.8 (Y)128.9 (,)-0.1 ( )36.8 (Y)99.8 (ashiro H, et al. Incidence survey of)]TJ 2.175 -1.25 Td (Kawasaki disease in 1997 and 1998 in Japan. Pediatrics)Tj 0 Tc 0 Tw T* (2001;107:E33.)Tj -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(22.)-875.1 (Dhillon R, Newton L, Rudd PT)73.9 (, Hall SM. Management of)]TJ 2.175 -1.25 Td [(Kawasaki disease in the British Isles. )54.8 (Arch Dis Child )]TJ 0 Tc 0 Tw T* (1993;69:637-8.)Tj -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(23.)-875.1 (Pelkonen P)110.7 (, Salo E. Epidemiology of Kawasaki disease. Clin Exp)]TJ 2.175 -1.25 Td (Rheumatol 1994;12 Suppl 10:S83-S85.)Tj -2.175 -1.25 Td [(24.)-875.1 (Schiller B, Fasth )54.8 (A, Bjorkhem G, Elinder G. Kawasaki disease in)]TJ 2.175 -1.25 Td [(Sweden: incidence and clinical features. )54.8 (Acta Pediatr )]TJ 0 Tc 0 Tw T* (1995;84:769-74.)Tj -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(25.)-875.1 (Royle JA, )17.7 (W)39.8 (illiams K, Elliot E, et al. Kawasaki disease in)]TJ 2.175 -1.25 Td [(Australia, 1993-95. )54.8 (Arch Dis Child 1998;78:33-9.)]TJ -2.175 -1.25 Td [(26.)-875.1 (Johnson )54.8 (A, Gordon C, Palmer RG, Bacon P)91.7 (A. )17.7 (The prevalence and)]TJ 2.175 -1.25 Td (incidence of systemic lupus erythematosus in Birmingham,)Tj T* [(England. Relationship to ethnicity and country of birth. )54.8 (Arthritis)]TJ 0 Tc T* (Rheum 1995;38:551-8.)Tj -0.00011 Tc -2.175 -1.25 Td [(27.)-875.1 (Oddis CV)128.8 (, Conte CG, Steen )17.7 (VD, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)54.8 (. Incidence of)]TJ 2.175 -1.25 Td [(polymyositis-dermatomyositis: )54.8 (A)-220.1 (20-year study of hospital )]TJ T* [(diagnosed cases in )54.8 (Allegheny County)64.9 (, P)91.7 (A)-220.1 (1963-1982. J Rheumatol)]TJ 0 Tc 0 Tw T* (1990;17:1329-34.)Tj -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(28.)-875.1 (Huemer C, Huemer M, Dorner )17.7 (T)74 (, et al. Incidence of pediatric )]TJ 2.175 -1.25 Td [(rheumatic diseases in a regional population in )54.8 (Austria. J Rheumatol)]TJ 0 Tc 0 Tw T* [(2001;28:21)36.9 (16-9.)]TJ -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(29.)-875.1 (Kaipiainen-Seppanen O, Savolainen )54.8 (A. Incidence of chronic )]TJ 2.175 -1.25 Td (juvenile rheumatic diseases in Finland during 1980-1990. Clin Exp)Tj T* (Rheumatol 1996;14:441-4.)Tj -2.175 -1.25 Td [(30.)-875.1 (Pelkonen PM, Jalanko HJ, Lantto RK, et al. Incidence of systemic)]TJ 2.175 -1.25 Td [(connective tissue diseases in children: )54.8 (A)-220.1 (nationwide prospective)]TJ T* (study in Finland. J Rheumatol 1994;21:2143-6.)Tj -2.175 -1.25 Td [(31.)-875.1 (Fujikawa S, Okuni M. )54.8 (A)-220.1 (nationwide surveillance study of )]TJ 2.175 -1.25 Td [(rheumatic diseases among Japanese children. )54.8 (Acta Pediatr Jpn)]TJ 0 Tc 0 Tw T* (1997;39:242-4.)Tj -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(32.)-875.1 (Symmons DPM, Sills JA, Davis SM. )17.7 (The incidence of juvenile )]TJ 2.175 -1.25 Td [(dermatomyositis: Results of a nationwide study)64.8 (. Br J Rheumatol)]TJ 0 Tc 0 Tw T* (1995;34:732-6.)Tj -0.00011 Tc 0.02499 Tw -2.175 -1.25 Td [(33.)-875.1 (DeNardo BA, )17.7 (T)35 (ucker LB, Miller LC, Szer IS, Schaller JG.)]TJ 2.175 -1.25 Td (Demography of a regional pediatric rheumatology patient )Tj T* (population. J Rheumatol 1994;21:1553-61.)Tj -2.175 -1.25 Td [(34.)-875.1 (Hanissian )54.8 (AS, Masi )54.8 (A)110.8 (T)74 (, Pitner SE, Cape CC, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)54.8 (.)]TJ 2.175 -1.25 Td [(Polymyositis and dermatomyositis in children: )54.8 (An epidemiological)]TJ T* (and clinical comparative analysis. J Rheumatol 1982;9:390-4.)Tj ET 0 0 0 1 K 52.97 77 m 557.97 77 l S 0 0 0 0 k 493.79 69.86 64.18 -15.66 re f* BT 0 0 0 1 k /T1_3 1 Tf 0 Tc 0 Tw 8 0 0 8 540.968 56.9344 Tm (2299)Tj ET 0 0 0 0 k 53.03 71 203 -15.66 re f* BT 0 0 0 1 k /T1_3 1 Tf -0.00011 Tc 0.02499 Tw 8 0 0 8 54.032 58.0696 Tm (Dolezalov\207, et al: Incidence of childhood vasculitis)Tj ET 0 0 0 0 k /GS0 gs 103.25 82.57 407.5 -10.83 re f* 0.5 w 103.25 82.57 407.5 -10.83 re S Q Q q 0 0 612 792 re W n BT 0 0 0 rg /GS2 gs /T1_4 8 Tf 112.368 73 Td (Personal, non-commercial use only. The Journal of Rheumatology. Copyri\ ght \251 2004. All rights reserved.)Tj ET Q BT 0 g /GS2 gs /T1_5 1 Tf 10 0 0 10 540 17 Tm ( )Tj 0 0.48627 0.77255 rg /GS2 gs -7.22298 0 Td (www.jrheum.org)Tj 0 g /GS2 gs -16.72996 0 Td (Downloaded on March 28, 2024 from )Tj ET endstream endobj 21 0 obj <>stream 8;Z\6>B0g##ikn#j>ril=$kP!p3P2[cB=tt)i'1[_X=W+,;Zau5^V/PlhBZ2l0XPK Qa[L,*GgLUf\3;amdnMX`*5FmjUCH]jE3Ts&_4B+LK@pOnoRlg";DB>BbIVLOf:`t !B5C@OT;ch^El6kNqrt$n;BOO):Cf)3'HlA*HXl=oni'DXVb!(0Us R([d-q0o^Dd4<[](XQTEr%S^>oJFYqqTkcE3hZZZJ\.qIR>fFJbS%elCW q4sT'GFIB;_"gdDD_ajP#)]a[5JTLn5m)J1hQj_RLK_1nj]LcM854KP-D$DcmI")0 rMd.9'X6q;^J==8&;N1b\Mj,s:%OMc5J'm?W%'f3c>*\W.!0hGSigRAa%_lt7)*3# `D3?]N7N\^SB=QMT9.;J9kD!XY1#tP_6$CeYrU1I5i3q[..9/GkUd/UR?=%H"dUHu -g/2u+VF<0ori()/8eC"Mkm/f>^U7koh#kV2&EL81>X-C'NXpcm#+gGp>k697JWrt=#cLAPa0N^c4A(Q =>-kkp=a;*?rJ`!iVtA\O4A4mc`_T-2RB"V!9=6;#6~> endstream endobj 25 0 obj [/Indexed/DeviceRGB 255 24 0 R] endobj 24 0 obj <>stream J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T (7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4 PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD' dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\ 9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue> gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R endstream endobj 94 0 obj <> endobj 68 0 obj <> endobj 48 0 obj <> endobj 46 0 obj <> endobj 83 0 obj <> endobj 128 0 obj <> endobj 49 0 obj <> endobj 76 0 obj <>stream HUyTSgKQG# yR\zDd*ZjAP!d$( lBE@`RuEE:vZi9j{_1KϜ?s9{=w~9:`8nX64l^(M(_/?a0gg8>XLygzׅ? "A뗶9[.Z\_ ,sV(?SWtS˱撑,FC.H/+V˵ n-NCEeAJd6Y^)./k_s6Uhe"r< 5KN2F0)8p^<{l-F՜Q.DO _JnY$DBmaqzuNuN[e VAQy>dsxEVțpmPCnZ{1oFFFM's> цSY<Q2< X9d Fm~;gxP_!M=^ԓ$qsӚo'.gQ#;ۛgxE~am^I^Qͻ{pG{ )iƕa"Ro[2b$Vwm3qu3 zښ/PnoQhɚ9YU-wzl>oߩ+兔[ 6G߲%jΙm>qx{0l|2,jŇǠQ77%ssmHCQ3e?Q_;n=@i3n:Hd`Kljp~_~Rln haE8~1Y?'Jئziti]NSD& UЫ?pX[C٧lu]0*`M hGۏH6fSKqD/6\2S!~x} {|it +JBbi|@ )~=VM46O!RKYƼ;L8b%XW[0=LM*ՅђF3!AiFZ7{1`6\|cLH(X{6i@Ǹ\mHL49EP] q9Æ/:k<~PjlPjsׅ JHi(y5Ny;8y)l7rz!xaN 0\msisH D9NQf"XsK¾k~Ifz!lm:x߄W{PSwƛ\w, 05>FtV]V*VA(`&<#Q)QkJHǬ؝u2L{;E^.C%9+|2*oxY2I.!rXC ns~_+Hucf,-z5 U~f>v,i+.+a]M ݹF+{+SJwD. c[%3g(Q_ST sZIIVjTy. Fڡ S~ʀ,ʓsdqRX<[1܆f̋_d~A94b;-u O 饥xJX.uxyʣB\qs1%M7v(P!ײmtc7ktG: P++`YI,q2ɻ'`-:}^QtٰOJħ0niU*ay VN ȇP8ZF07$gТiT6dkW~*C[~!NIz.Qnh JfeB 5J=VO_Vq( 0;/e<ġoҴ*btcVKwA/=c2^-:);ԧF;f-C6!S6RVJhJ/6&g KB~/qj -a3}aU>MbO2eѕ6o!tܳinܱ.ZWHHEs6 NmoϠD,0Rx)OiCv|uUg,,C]1CRV0ܖ\S&rSZWQzRq?kϽ鶌}Srh)cV{QOV:CwFy,"4 (=j:ܓ?xINJ)trm$+qiTCH#X"ྃ1FdLEF];mwDl79+)wn[~JBKT>.X{)Sk=1Tjg\FSoLC^h+څ_7myZ5HMɮ!.(7}@)$eR_ }RrY8QG0GX{餩UKJPĨ裎\'cTL{qJRBM\ kІ!י} 3:w3'#H%+%KIUkU1NjWeF.MUKM\7 uM]{U4S"5lV<ۿmp23]oz9b$@yrUrO?'ԝ6<i%\ZWuq1{% `ª91;H_E*IG?`"ܥlMHM3HˌRޢW2yAa_'i^-njer^0OI8Mzw|t `/P9K1vGNyș͂U9 j9ξ!>,&˳5٫ws%:#jKZ gߩ<8QHWFSUP5'>^xPx\)@qAs<ɴ-> .ѽn`+,lG+cbAljQw5WǽgdBjY'E7˸a͞u3/[@{z1u=ƙu0"oE ;#D ~bE!Vg8R7E"kFOQ;
E*IG?`"ܥlMHM3HˌRޢW2yAa_'i^-njer^0OI8Mzw|t `/P9K1vGNyș͂U9 j9ξ!>,&˳5٫ws%:#jKZ gߩ<8QHWFSUP5'>^xPx\)@qAs<ɴ-> .ѽn`+,lG+cbAljQw5WǽgdBjY'E7˸a͞u3/[@{z1u=ƙu0"oE ;#D ~bE!Vg8R7E"kFOQ;